Huatai United Securities Co., Ltd
Special verification report on the deposit and actual use of raised funds in Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) 2021
Huatai United Securities Co., Ltd. (hereinafter referred to as “Huatai United Securities” or “sponsor”) as the sponsor of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) (hereinafter referred to as ” Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) “, “company” or “issuer”) for non-public issuance of A-share shares, in accordance with the measures for the Administration of securities issuance and listing recommendation business and the guidelines for the supervision of listed companies No. 2 – regulatory requirements for the management and use of raised funds of listed companies The deposit and actual use of the raised funds in Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) 2021 were verified in accordance with the provisions of laws and regulations such as the guidelines for self discipline supervision of listed companies of Shanghai Stock Exchange No. 1 – standardized operation. The verification results are as follows:
1、 Basic information of raised funds
(I) the actual amount of funds raised and the time of receipt of funds after deducting the issuance expenses
According to the resolutions of the 8th meeting of the 6th board of directors and the 13th meeting of the 6th board of directors of the company, and approved by the reply on approving Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) non-public development of shares issued by the CSRC (zjxk [2016] No. 826), the company issued 334711699 RMB ordinary shares (A shares), with a par value of 1.00 yuan per share (RMB, the same below), and increased the share capital by 33471169900 yuan, The changed share capital is 162579094900 yuan. As of August 11, 2016, the company had issued 334711699 ordinary shares (A shares) in RMB through non-public offering, with an issue price of 23.56 yuan per share, and the total amount of funds raised was 788580762844 yuan. After deducting 2236110011 yuan of various issuance expenses, the net amount of funds actually raised was 786344652833 yuan. Among them, the newly increased share capital was 334711699 yuan and the increased capital reserve was 752873482933 yuan. The above raised funds have been verified by Lixin Certified Public Accountants (special general partnership) and issued a capital verification report (xksbz [2016] No. 410605).
(II) use amount and current balance of raised funds
As of December 31, 2021, the use of the company’s raised funds is as follows:
Amount of project raised funds
(10000 yuan)
Net proceeds 78634465
Less: accumulated expenditure of raised investment projects (including self owned capital investment in the early stage of replacement) 62214635
Including: accumulated expenditure before December 31, 2020: 52013465
Cumulative expenditure in 2021: 10201170
Less: bank service charge expenditure 30.83
Less: net purchase of principal guaranteed financial products with idle raised funds-
Plus: the accumulated interest income of special account and principal guaranteed financial products is 5382363
As of December 31, 2021, the balance of the special account for raised funds was 21799110
In 2021, the actual use of the raised funds by the company and the main enterprises implementing the fund-raising projects of its subordinates was 1020117 million yuan; As of December 31, 2021, the total amount of raised funds invested has been 6221463500 yuan (including the investment of self owned funds in the early stage of replacement). For details, see attached table 1 comparison table of use of raised funds and attached table 2 table of change of investment projects of raised funds.
2、 Management of raised funds
In order to standardize the management and use of the company’s raised funds and protect the rights and interests of investors, the company formulated the measures for the management of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) raised funds (“measures for the management of raised funds”), which was deliberated and adopted by the company’s first extraordinary general meeting in 2015.
In accordance with the regulations of the regulatory authorities and the requirements of the measures for the management of raised funds, the company has set up branches in Guangzhou Jincheng sub branch of Shanghai Pudong Development Bank, Guangzhou Shamian sub branch of Guangdong Development Bank Co., Ltd. (hereinafter referred to as “Shamian sub branch of Guangdong Development Bank”), China Everbright Bank Company Limited Co.Ltd(601818) Guangzhou Yangji sub branch (hereinafter referred to as ” China Everbright Bank Company Limited Co.Ltd(601818) Yangji sub branch”) China Citic Bank Corporation Limited(601998) Guangzhou Branch (hereinafter referred to as ” China Citic Bank Corporation Limited(601998) Guangzhou Branch”) has established six special accounts for raised funds, and signed the tripartite supervision agreement on the storage of special accounts for raised funds with the above-mentioned banks with Huatai United Securities Co., Ltd. on August 29, 2016. In order to ensure the standardization of the management and use of the company’s raised funds and protect the rights and interests of investors, according to the provisions of relevant laws and regulations, Guangzhou wanglaojida Health Industry Co., Ltd. (hereinafter referred to as “wanglaojida health company”), Guangzhou Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) Mingxing Pharmaceutical Co., Ltd. (hereinafter referred to as “Mingxing pharmaceutical”) Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) he Jigong pharmaceutical factory (hereinafter referred to as “he Jigong pharmaceutical factory”) has set up special accounts for raised funds in China Everbright Bank Company Limited Co.Ltd(601818) Yangji sub branch and Shamian sub branch of Guangdong Development Bank respectively, and signed the four party supervision agreement on the storage of special accounts for raised funds with Huatai United Securities, the company and the above-mentioned banks on January 24, 2017 Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332)
General Pharmaceutical Factory (hereinafter referred to as ” Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) General Pharmaceutical Factory”), Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332)
Guangzhou Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) chemical pharmaceutical factory (hereinafter referred to as “chemical pharmaceutical factory”) and Guangzhou Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) Hanfang Modern Pharmaceutical Co., Ltd
Ltd. (hereinafter referred to as “Guangzhou Hanfang”) was established on July 12, 2018 and September 25, 2018 respectively
And on August 20, 2019, signed with Huatai United Securities Co., Ltd. and Guangzhou Branch of Shanghai Pudong Development Bank
Four party supervision agreement on the storage of raised funds in the special account; Guangzhou Caizhilin Pharmaceutical Co., Ltd. (hereinafter referred to as “Caizhilin”)
Zhilin Pharmaceutical Co., Ltd.) signed with Huatai United Securities, the company and China Citic Bank Corporation Limited(601998) Guangzhou Branch on September 11, 2019
Signed the quadripartite supervision agreement on the storage of raised funds in the special account; Wanglaoji health Co., Ltd. will
The special bank account for the raised funds of the “channel construction and brand construction” project was changed from China Everbright Bank Company Limited Co.Ltd(601818) Yangji sub branch to
Development Zone sub branch of Bank of Guangzhou Co., Ltd. (hereinafter referred to as “Development Zone sub branch of Bank of Guangzhou”), and
On February 25, 2020, the company signed the capital raising agreement with Huatai United Securities, the company and the Development Zone Branch of Bank of Guangzhou
Four party supervision agreement on special account storage of gold; Guangzhou Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) Baidi biomedical Co., Ltd. (hereinafter referred to as “Guangdi”)
On May 7, 2020, Baidi, Mingxing pharmaceutical and Caizhilin pharmaceutical cooperated with Huatai United Securities, the company
Guangzhou Branch of Shanghai Pudong Development Bank signed the four party supervision agreement on the storage of special account for raised funds; Guangyaobai
Yunshan Chemical Pharmaceutical (Zhuhai) Co., Ltd. and Huatai United Securities Co., Ltd. on January 8, 2021
Guangzhou Branch of Shanghai Pudong Development Bank signed the four party supervision agreement on the storage of special account for raised funds; Guangzhou medicine
On August 2029, Huatai Pharmaceutical Research Institute Co., Ltd. (hereinafter referred to as “China Pharmaceutical Research Institute”)
Securities, the company and Guangzhou Branch of Shanghai Pudong Development Bank signed the four party supervision agreement on the storage of special account for raised funds;
Gansu Guangyao Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(600332) traditional Chinese Medicine Technology Co., Ltd. and Huatai United Securities, company
Guangzhou Branch of Shanghai Pudong Development Bank signed the four party supervision agreement on the storage of special account for raised funds.
As of December 31, 2021, the specific deposit of raised funds is as follows:
account
Account name deposit bank fund purpose bank account number / account balance use fixed deposit certificate (10000 yuan) status
The company’s Shanghai Pudong Development Bank Guangda “Da Nan Yao” R & D platform was built 82090158 Ping An Bank Co.Ltd(000001) 37 live 10295172 normal Jincheng sub branch was set up for use in the project period
Company Guangfa Bank Co., Ltd. “Da Nan Yao” production base I 955088 Lijiang Yulong Tourism Co.Ltd(002033) 6100164 live 7660357 normal Department Guangzhou Tancun sub branch (note) phase I construction project
Company Shanghai Pudong Development Bank Guangxian pharmaceutical logistics service extension 82090158 Csg Holding Co.Ltd(000012) 9 live – has been noted that the extension project of Jincheng sub branch in Jinzhou has been sold for a long time
China China Everbright Bank Company Limited Co.Ltd(601818) Co., Ltd. has channel construction and brand construction 38670188 Xi’An Catering Co.Ltd(000721) 61 live 1215065 normal use of Guangzhou Yangji sub branch project
81109010130 Shenzhen Zhongzhuang Construction Group Co.Ltd(002822) 18 information platform construction project of China Citic Bank Corporation Limited(601998) Co., Ltd. – noted
account
Account name deposit bank fund purpose bank account number / account balance use fixed deposit certificate (10000 yuan) status
Guangzhou Branch Sales Department
Company China Citic Bank Corporation Limited(601998) Co., Ltd. supplementary working capital project 81109010124 Shenzhen Zhongzhuang Construction Group Co.Ltd(002822) 16 live 116305 normal use of Guangzhou Branch
Wang Laoji Greater China China Everbright Bank Company Limited Co.Ltd(601818) Co., Ltd. has channel construction and brand construction 3867018800074881 activity – the project sales of Guangzhou Yangji sub branch of health company Co., Ltd. has been noted
Wanglaojida Bank of Guangzhou Co., Ltd. public channel construction and brand construction 8 Shandong Ruyi Woolen Garment Group Co.Ltd(002193) 85702988 live – note health company development zone sub branch project sales
Mingxing pharmaceutical Guangfa Bank Co., Ltd
